title: QT Prolongation and Anticancer Drugs: Is it a Cardiologist's Worry? The Oncologist's Point of View.
abstract: Currently, many novel therapies are available for physicians treating cancer; some of them are associated with adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this issue. We report a review of old and new commonly used agents with torsadogenic potential.
authors.forename: Francesca
authors.initials: F
authors.lastname: Aroldi
authors.forename: Tiziana
authors.initials: T
authors.lastname: Prochilo
authors.forename: Elena
authors.initials: E
authors.lastname: Bonini
authors.affiliation: UO di Oncologia, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Zaniboni
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001291:Attitude of Health Personnel; D002309:Cardiology; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D008495:Medical Oncology; D016171:Torsades de Pointes / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents